stockrow
Friday 6 November 2026
Export MNOV’s income statement to Excel — free account
MediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023.
- Revenue
- +240.6%
- EPS
- +28.6%
- Free cash flow
- +16.8%
Quarter to June 2026, against a year earlier
1.46
0.01
+0.69%
Follow MNOV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 4 | — | 1 | — | 0 | 1 | (43.6%) | 1 | 0 | 43 | +370.6% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 100.00 | — | 7.59 | 37.76 | +7.6 pt | ||||||
| EBT | (11) | (13) | (15) | (13) | (14) | (10) | (14) | (9) | (11) | (12) | (11) | +1.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (250.94) | 0.00 | (856.85) | 0.00 | (2,927.02) | (1,167.66) | (2,927.0) pt | ||||||
| Net income | (11) | (11) | (15) | (13) | (14) | (10) | (14) | (9) | (11) | (12) | (11) | +1.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.02 | 0.00 | 0.01 | 0.02 | n/m | |||||
| Earnings | (0.33) | (0.32) | (0.36) | (0.30) | (0.31) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) | (0.21) | (3.5%) | ||||||
| Cash flow | (0.20) | (0.20) | (0.22) | (0.21) | (0.24) | (0.19) | (0.26) | (0.15) | (0.22) | (0.20) | (0.19) | +0.1% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | (30.4%) | ||||||
| Free cash flow | (0.20) | (0.20) | (0.22) | (0.21) | (0.24) | (0.19) | 0.14 | (0.15) | (0.22) | (0.20) | (0.19) | (0.1%) | ||||||
| Book value | 1.05 | 1.10 | 1.78 | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | 1.07 | 0.85 | 0.76 | (2.3%) | ||||||
| Shares, m | 33 | 35 | 41 | 43 | 44 | 49 | 49 | 49 | 49 | 49 | 49 | +4.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 12.97 | — | 7.33 | — | 45.60 | 78.08 | 22.0 | ||||||
| P/B | — | — | — | — | — | 1.56 | — | 1.30 | — | 1.55 | 1.93 | 1.5 | ||||||
| EV/Sales | — | — | — | — | — | 5.86 | — | 2.71 | — | 23.74 | 50.46 | 10.8 | ||||||
| EV/FCF | — | — | — | — | — | (6.23) | — | 2.41 | — | (3.41) | (5.09) | (2.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (7) | (7) | (9) | (9) | (11) | (9) | (13) | (7) | (11) | (10) | (9) | +4.6% | |||||
| Capex | 0 | — | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 | (31.2%) | ||||||
| Free cash flow | (7) | (7) | (9) | (9) | (11) | (9) | 7 | (7) | (11) | (10) | (9) | +4.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 23 | 25 | 61 | 62 | 59 | 69 | 56 | 48 | 38 | 27 | 23 | +1.8% | |||||
| Net debt | (24) | (28) | (62) | (64) | (60) | (71) | (58) | (51) | (40) | (31) | (25) | +2.8% | ||||||
| Shareholders’ equity | 35 | 39 | 73 | 75 | 71 | 84 | 70 | 62 | 53 | 42 | 37 | +2.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (27.96) | (26.82) | (24.33) | (16.55) | (17.92) | (12.45) | (17.42) | (12.21) | (18.09) | (23.65) | (23.83) | +4.3 pt | |||||
| ROIC | (65.31) | (76.45) | (90.25) | (78.99) | (78.49) | (52.14) | (77.78) | (54.38) | (65.23) | (77.01) | (62.48) | (11.7) pt | ||||||
| ROE | (32.30) | (30.51) | (26.26) | (17.49) | (18.95) | (13.08) | (18.28) | (12.93) | (19.24) | (25.50) | (25.56) | +6.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 10 | 9 | 9 | 8 | — | 11 | 13 | 13 | 13 | 6 | — | (5.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.37 | 0.00 | 0.08 | 0.00 | 0.07 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
MediciNova, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRXS Neuraxis, Inc. | $76.7M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| CLLS Cellectis S.A. | $74.5M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| OKYO OKYO Pharma Limited Sponsored ADR | $73.5M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | Compare |
| TNYA Tenaya Therapeutics, Inc. | $72.0M | — (loss-making) | — | — | n/m | −13.18% (below 0%: shrinking) | 100.00% | (1,153.33%) | Compare |
| RANI Rani Therapeutics Holdings, Inc. | $72.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −55.29% (below 0%: shrinking) | 100.00% | (516.86%) | Compare |
| MNOV MediciNova, Inc. | $71.4M | — (loss-making) | — (loss-making) | +240.56% (above 0%: growing) | n/m | +16.75% (above 0%: growing) | 69.33% | (554.36%) | |
| NTRB Nutriband Inc. | $67.8M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $67.3M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CSBR Champions Oncology, Inc. | $66.3M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| Median of peers | $72.0M | — | — | 0.00% | — | −0.29% | 68.21% | (203.57%) |
Pay and ownership Proxy statement filed 29 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.76m | 1.34m | 63.90 |
| 2024 | 1.41m | 1.61m | 102.44 |
| 2023 | 1.39m | 1.15m | 73.17 |
Ownership
Directors and executive officers, together
14.00%
Yuichi Iwaki, M.D., Ph.D.
8.80%
Kazuko Matsuda, M.D., Ph.D., MPH
5.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement